LATS1 and metabolic dysfunction-associated steatohepatitis: Experimental evidence demonstrates cholesterol overload-induced calcium signaling activation stimulates RhoA-mediated LATS1/2 inhibition, culminating in transcriptional upregulation of TAZ/YAP proteins that drive NASH-associated fibrogenesis [84].